Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global osteoarthritis pain market. The report identifies the key trends shaping and driving the global osteoarthritis pain market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global Osteoarthritis pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.

Scope

The report provides information on the key drivers and challenges of the osteoarthritis pain market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis pain market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as COX-II inhibitors, TRPV antagonists, Opiod receptor agonists, anti NGF mAB and CB-2 agonists.
• Analysis of the current and future competition in the seven key countries osteoarthritis pain market. Key market players covered are Abbott Laboratories, Adolor Corporation, Cephalon, Inc., Endo Pharmaceuticals, Elite Pharmaceuticals, Glenmark Pharmaceuticals, Grunenthal GMBH, Johnson & Johnson Pharmaceuticals Ltd., Pfizer, Inc., SantaSolve AS, and Sanofi-Aventis.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis pain therapeutics market.
• Analysis of key recent licensing and partnership agreements in osteoarthritis pain market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global osteoarthritis pain market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis pain market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global osteoarthritis pain market landscape? – Identify, understand and capitalize.

Table of contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 OA Pain Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 OA Pain 10
2.2 Epidemiology 10
2.3 Etiology and Pathophysiology 11
2.3.1 Progression of the Disease 11
2.4 Signs and Symptoms 14
2.5 Diagnosis 15
2.5.1 Commonly Used Diagnosis Tests 15
2.6 Treatment and Management Options 16
2.7 GlobalData Pipeline Report Guidance 18

3 OA PainTherapeutics - Market Characterization 19
3.1 OA Pain Therapeutics Market Size (2005-2010) – Global 19
3.2 OA Pain Therapeutics Market Forecast (2010-2017) – Global 20
3.3 OA Pain Therapeutics Market Size (2005-2010) – The US 21
3.4 OA Pain Therapeutics Market Forecast (2010-2017) – The US 22
3.5 OA Pain Therapeutics Market Size (2005-2010) – France 23
3.6 OA Pain Therapeutics Market Forecast (2010-2017) – France 24
3.7 OA Pain Therapeutics Market Size (2005-2010) – Germany 25
3.8 OA Pain Therapeutics Market Forecast (2010-2017) – Germany 26
3.9 OA Pain Therapeutics Market Size (2005-2010) – Italy 27
3.10 OA pain Therapeutics Market Forecast (2010-2017) – Italy 28
3.11 OA Pain Therapeutics Market Size (2005-2010) – Spain 29
3.12 OA Pain Therapeutics Market Forecast (2010-2017) – Spain 30
3.13 OA Pain Therapeutics Market Size (2005-2010) – The UK 31
3.14 OA Pain Therapeutics Market Forecast (2010-2017) – The UK 32
3.15 OA Pain Therapeutics Market Size (2005-2010) – Japan 33
3.16 OA Pain Therapeutics Market Forecast (2010-2017) – Japan 34
3.17 Drivers and Barriers for the OA Pain Therapeutics Market 35
3.17.1 Drivers for the OA Pain Therapeutics Market 35
3.17.2 Barriers for the OA Pain Therapeutics Market 35
3.18 Opportunity and Unmet Need Analysis 36
3.19 Key Takeaway 37

4 OA Pain Therapeutics - Competitive Assessment 38
4.1 Overview 38
4.2 Strategic Competitor Assessment 38
4.3 Product Profiles for the Major Marketed Products in the OA PainTherapeutics Market 39
4.3.1 Celebrex (celecoxib) 39
4.3.2 Voltaren Gel (diclofenac sodium) 40
4.3.3 Morphine 41
4.3.4 Hyalgan (sodium hyaluronate) 42
4.4 Key Takeaway 42

5 OA Pain Therapeutics - Pipeline Assessment 43
5.1 Overview 43
5.2 Strategic Pipeline Assessment 43
5.3 OA Pain Therapeutics Pipeline – Pipeline by Phases of Development 43
5.3.1 OA Pain Therapeutics – Regulatory Filed Products 44
5.3.2 OA Pain Therapeutics – Phase III Pipeline 44
5.3.3 OA Pain Therapeutics – Phase II Pipeline 45
5.3.4 OA Pain Therapeutics – Phase I Pipeline 45
5.3.5 OA Pain Market – Discovery and Pre-Clinical Pipeline 46
5.3.6 Technology Trends Analytic Framework 47
5.4 OA Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action 49
5.5 OA Pain Therapeutics – Promising Drugs Under Clinical Development 49
5.6 Molecule Profile for Promising Drugs Under Clinical Development 50
5.6.1 2PX 50
5.6.2 Nucynta ER (tapentadol) 51
5.7 Key Takeaway 51

6 OA Pain Therapeutics - Clinical Trials Mapping 52
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 52
6.2 Clinical Trials by Phase 53
6.3 Clinical Trials by Trial Status 54
6.4 Prominent Sponsors 55
6.5 Top Companies Participating in OA pain Therapeutics Clinical Trials 57

7 Strategic Assessment 58
7.1 Key Events Impacting the Future Market 58
7.2 OA Pain Therapeutics: Implications for Future Market Competition 59

8 OA Pain Therapeutics - Future Players 60
8.1 Introduction 60
8.2 Company Profiles 61
8.2.1 Abbott Laboratories 61
8.2.2 Adolor Corporation 65
8.2.3 Cephalon, Inc. 66
8.2.4 Endo Pharmaceuticals 68
8.2.5 Elite Pharmaceuticals 70
8.2.6 Glenmark Pharmaceuticals 72
8.2.7 Grunenthal GmbH 74
8.2.8 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 76
8.2.9 Pfizer, Inc. 77
8.2.10 Sanofi 81
8.2.11 Other Companies in the OA Pain Therapeutics Market 84

9 OA Pain Therapeutics - Licensing and Partnership Deals 85

10 OA Pain Therapeutics - Appendix 86
10.1 Market Definitions 86
10.2 Abbreviations 86
10.3 Methodology 87
10.3.1 Coverage 87
10.3.2 Secondary Research 87
10.3.3 Forecasting 88
10.3.4 Primary Research 90
10.3.5 Expert Panel Validation 91
10.4 Contact Us 91
10.5 Disclaimer 91
10.6 Bibliography 91

List of Tables

Table 1: OA Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19
Table 2: OA Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 20
Table 3: OA Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 21
Table 4: OA Pain Therapeutics Market, The US, Forecasts ($bn), 2010–2017 22
Table 5: OA Pain Therapeutics Market, France, Revenue ($m), 2005–2010 23
Table 6: OA Pain Therapeutics Market, France, Forecasts ($m), 2010–2017 24
Table 7: OA Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 25
Table 8: OA Pain Therapeutics Market, Germany, Forecasts ($m), 2010–2017 26
Table 9: OA Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 27
Table 10: OA Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017 28
Table 11: OA Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 29
Table 12: OA Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017 30
Table 13: OA Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 31
Table 14: OA Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017 32
Table 15: OA Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33
Table 16: OA Pain Therapeutics Market, Japan, Forecasts ($m), 2010–2017 34
Table 17: OA Pain Therapeutics – Regulatory Filed Products, 2011 44
Table 18: OA Pain Therapeutics – Phase III Pipeline, 2011 44
Table 19: OA Pain Therapeutics – Phase II Pipeline, 2011 45
Table 20: OA Pain Therapeutics – Phase I Pipeline, 2011 45
Table 21: OA PainTherapeutics – Discovery and Pre-Clinical Pipeline, 2011 46
Table 22: OA Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011 49
Table 23: OA Pain Therapeutics – Clinical Trials by Country, 2011 52
Table 24: OA Pain Therapeutics – Clinical Trials by Phase, 2011 53
Table 25: OA Pain Therapeutics – Clinical Trials by Status, 2011 54
Table 26: OA Pain Therapeutics, Overall Sponsors 55
Table 27: OA Pain Therapeutics, Most Prominent Sponsors 56
Table 28: OA Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 57
Table 29: Acura Pharmaceuticals – Pain Management, Pipeline, 2011 64
Table 30: Abbott Laboratories – Deals, 2009-2011 64
Table 31: OA Pain Therapeutics, Adolor Corporation, Pain Management Pipeline, 2011 66
Table 32: Adolor Corporation, Deals, 2009-2011 66
Table 33: OA Pain Therapeutics, Cephalon, Inc., OA pain Therapeutics Pipeline, 2011 68
Table 34: Cephalon, Inc., Deals, 2009-2011 68
Table 35: Endo Pharmaceuticals, Pain Management Therapeutic Pipeline, 2011 69
Table 36: Endo Pharmaceuticals, Deals, 2009-2011 70
Table 37: OA Pain Therapeutics, Elite Pharmaceuticals Pain Management Pipeline, 2011 71
Table 38: Elite Pharmaceuticals OA Pain Pipeline, 2011 71
Table 39: Elite Pharmaceuticals, Deals, 2009-2011 72
Table 40: Glenmark Pharmaceuticals, OA Pain Pipeline, 2011 73
Table 41: Glenmark Pharmaceuticals, Deals, 2009-2011 74
Table 42: Grunenthal GMBH, Pain Management Pipeline, 2011 75
Table 43: Grunenthal GmbH – Deals, 2009-2011 75
Table 44: Johnson & Johnson Pharmaceutical R&D L.L.C., OA Pain Management Pipeline, 2011 76
Table 45: J&JPRD, Deals, 2009-2011 77
Table 46: Pfizer, Pain Management Pipeline, 2011 79
Table 47: Pfizer, OA Pain Pipeline, 2011 79
Table 48: Pfizer, Inc., Deals, 2009-2011 80
Table 49: OA Pain Therapeutics, Sanofi Pain Management Pipeline, 2011 82
Table 50: Sanofi, Deals, 2009-2011 83
Table 51: OA Pain Therapeutics Market – Future Players 84
Table 52: Licensing and Partnership Deals, 2008-2011 85

List of Figures

Figure 1:Osteoarthritis of the Knee 7
Figure 2:Osteoarthritis of the Knee 8
Figure 3: Osteoarthritis of the Hand, Heberden’s Nodes 8
Figure 4: Osteoarthritis of the Hand, Bouchard’s Nodes 9
Figure 5: Osteoarthritis of the Hip 9
Figure 6:OA Pain Pathophysiology 11
Figure 7:OA Pain Pathophysiology 12
Figure 8:OA Pain Pathophysiology 12
Figure 9:OA Pain Pathophysiology 13
Figure 10:OA Pain Pathophysiology 14
Figure 11:OA Pain, Treatment Pattern 17
Figure 12: OA Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 19
Figure 13: OA Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 20
Figure 14: OA Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 21
Figure 15: OA Pain Therapeutics Market, The US, Forecast ($bn), 2010–2017 22
Figure 16: OA Pain Therapeutics Market, France, Revenue ($m), 2005–2010 23
Figure 17: OA Pain Therapeutics Market, France, Forecast ($m), 2010–2017 24
Figure 18: OA Pain Therapeutics Market, Germany , Revenue ($m), 2005–2010 25
Figure 19: OA Pain Therapeutics Market, Germany, Forecast ($m), 2010–2017 26
Figure 20: OA Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 27
Figure 21: OA Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017 28
Figure 22: OA Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 29
Figure 23: OA Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017 30
Figure 24: OA Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 31
Figure 25: OA Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017 32
Figure 26: OA Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 33
Figure 27: OA Pain Therapeutics Market, Japan, Forecast ($m), 2010–2017 34
Figure 28: Opportunity and Unmet Need in the OA Pain Therapeutics Market,2010 36
Figure 29: OA Pain Therapeutics – Strategic Competitor Assessment, 2011 38
Figure 30: OA Pain Therapeutics – Pipeline by Phase of Development, 2011 43
Figure 31: OA Pain Therapeutics – Technology Trends Analytics Framework, 2011 47
Figure 32: OA Pain Therapeutics – Technology Trends Analytics Framework – Description, 2011 48
Figure 33: OA Pain Therapeutics – Pipeline by Mechanism of Action, 2011 49
Figure 34: OA Pain Therapeutics – Clinical Trials by Country, 2011 52
Figure 35: OA Pain Therapeutics – Clinical Trials by Phase, 2011 53
Figure 36: OA Pain Therapeutics – Clinical Trials by Status, 2011 54
Figure 37: OA Pain Therapeutics – Overall Sponsors, 2011 55
Figure 38: OA Pain Therapeutics – Prominent Sponsors, 2011 56
Figure 39:OA Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 57
Figure 40: OA Pain Therapeutics Market, Drivers and Restraints, 2011 58
Figure 41: Implications for Future Market Competition in the OA pain Market, 2011 59
Figure 42: OA PainTherapeutics Market – Pipeline by Company, 2011 60
Figure 43: GlobalData Market Forecasting Model 90